June 18, 2026
4 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
VIDEO: Alpha-emitting radioantibody lowers PSA in castration-resistant prostate cancer
CHICAGO — In this video, Michael J. Morris, MD, FASCO, discusses results of the phase 2 CONVERGE-01 trial evaluating an alpha-emitting radioantibody for patients with metastatic castration-resistant prostate cancer. Treatment effects also included a decline in prostate-specific antigen. Findings from the study, which assessed the safety and efficacy of Ac-225 rosopatamab tetraxetan (CONV01-alpha,
291 words~1 min read
